Click here for slides on this topic


ADVANCE Study

Abbreviation for the Action in Diabetes and Vascular Disease: Pretarax and Diamicron Modified Release Controlled Evaluation study.
The following content matched the glossary term: ADVANCE Study

AHA ADA prevention of CVD in T2D - Hypoglycemia & CVD

Top

Summary of evidence for hypoglycemia & cardiovascular disease (CVD) from the AHA ADA CVD prevention in type 2 diabetes guidelines.

NDEI.org Expert Commentary Silvio E. Inzucchi MD on the Association Between Severe Hypoglycemia

Top

EXPERT COMMENTARY Expert blog post from Silvio E. Inzucchi, MD: "This paper adds to a growing body of literature demonstrating the higher cardiovascular risk of patients with type 2 diabetes and a history of severe hypoglycemia"

ADVANCE-ON: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes

Top

Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;[epub ahead of print]. doi: 10.1056/NEJMoa1407963.

Fonseca commentary on ADVANCE, SOS, VADT

Top

Expert commentary from NDEI Education Council Member Vivian A. Fonseca, MD, on data from post-hoc analyses of ADVANCE, SOS, and VADT.

Clinical Insights in Diabetes Newsletter December 2012

Top

Clinical Insights® in Diabetes newsletter December 2012 

Once-weekly exenatide vs once-daily liraglutide in DURATION-6, HDL-C and microvascular risk in ADVANCE, statins and valvular calcification in VADT, bariatric surgery and cardiovascular events in obesity and type 2 diabetes in SOS. 

Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy.

Top

Exclusive! Expert commentary webcast from Vivian Fonseca, MD, on this post-hoc analysis of ADVANCE. Morton J, Zoungas S, Li Q, et al; on behalf of the ADVANCE Collaborative Group. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy. Diabetes Care. 2012;35:2201-2206. Macro- and microvascular complications remain significant concerns in the treatment of patients with type 2 diabetes.

Clinical Insights in Diabetes Newsletter September 2012

Top

Clinical Insights® in Diabetes newsletter September 2012.

Intensive therapy in ACCORD-BP, Roux-en-Y gastric bypass for type 2 diabetes and obesity, diabetes and CVD mortality, and linagliptin and glimepiride for diabetes treatment.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 11, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 11, 2012

ORIGIN trial results, insulin and cancer, TINSAL-T2D results, and more.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 8, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 8, 2012

Diabetes and hypoglycemia, clinical management of diabetes, obesity treatment, diabetes in long-term care, and more. 

Glycemic Control: How Low Should You Go?

Top

Glycemic Control: How Low Should You Go? NDEI Education Council Co-Chair Burton E. Sobel, MD, provides expert commentary on the debate over intensive versus somewhat less intensive glycemic control in the context of a recent study by Zhao et al assessing the impact of hypoglycemia associated with antihyperglycemic medications on vascular risk in type 2 diabetes

1 2 Next 

Slide Library Results

Search Results for: ADVANCE Study Slides Found: 2
ADVANCE: Study Design
ADVANCE Substudy: Effects of BP Lowering and Intensive Glucose Control on Retinopathy